Srilakshmi Rebala, MD
Nephrology · Athens, GANPI 1730173733
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $957 of the $1,077 with a category attached, or 88.9%. It is spread thinly across 13 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in GA, where the typical reported total is $1,554.
Across 67 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$150
- Akebia Therapeutics Inc$134
- Vifor Pharma, Inc.$127
- Bayer$114
- Fresenius USA Marketing, Inc.$101
- Mallinckrodt Hospital Products Inc.$93
- plus $357 from 7 others
Across 5 payments — averaging $3291.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$16K
What the payments were for
- Food & beverage$95789%
- Education$12011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $150 |
| Akebia Therapeutics Inc | 7 | $134 |
| Vifor Pharma, Inc. | 7 | $127 |
| Bayer | 3 | $114 |
| Fresenius USA Marketing, Inc. | 6 | $101 |
| Mallinckrodt Hospital Products Inc. | 1 | $93 |
| Otsuka America Pharmaceutical, Inc. | 7 | $93 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $82 |
| Amgen(2 entities) | 4 | $62 |
| Travere Therapeutics, Inc. | 20 | $49 |
| AstraZeneca | 2 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
How this compares
$1,077 in reported general payments places this provider in the 40th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 46 | $137,375 |
| AuryxiaFerric Citrate | 15 | $36,056 |
| FarxigaDapagliflozin Propanediol | 46 | $34,477 |
| Sevelamer Carbonate | 149 | $20,947 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $12,587 |
| JardianceEmpagliflozin | 12 | $9,628 |
| ProsolParenteral Amino Acid 20% No.1 | 40 | $6,119 |
| Midodrine Hcl | 97 | $5,589 |
| Nifedipine ErNifedipine | 165 | $4,423 |
| ClinisolParenteral Amino Acid 15% No.5 | 16 | $2,989 |
| Potassium Chloride | 83 | $2,059 |
| Calcitriol | 56 | $1,916 |
| Metolazone | 34 | $1,771 |
| Furosemide | 292 | $1,538 |
| Febuxostat | 13 | $1,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $101 | $137,37546 claims |
| Akebia Therapeutics IncAuryxia | $134 | $36,05615 claims |
| AstraZenecaFarxiga | $35 | $34,47746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 388 nephrology providers in Georgia.
Other nephrology in Athens
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- Rajendran AlappanColumbus$87K
- William PaxtonLawrenceville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.